Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

John M. Burke, MD, hematologist, medical oncologist, Rocky Mountain Cancer Centers, Sarah Cannon Cancer Institute, discusses results from a United States community-based healthcare practitioner survey, highlighting best practices to overcoming challenges in initiating venetoclax (Venclexta) for patients with chronic lymphocytic leukemia. These findings were presented by Burke at the 2024 ASH Annual Meeting.